Testis specific transcription factor ZGCL-1
AssigneeZymoGenetics, Inc.
InventorsDavid P. Yee, Theresa A. Deisher
Life of this patent
Estimating the term…
Abstract
Novel ZGCL-1 transcription factor polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed. The polypeptides, agonists and antagonists may be used within methods for promoting the proliferation and/or differentiation of testis cells, and may also be used in the development of male-specific contraceptives and infertility treatments.
Claims17
An isolated polypeptide comprising a sequence of amino acid residues that is at least 80% identical in amino acid sequence to residues 1-479 of SEQ ID NO:2, wherein said sequence comprises a POZ domain corresponding to amino acid residues 61-178 of SEQ ID NO:2.
An isolated polypeptide according to claim 2, wherein said polypeptide is at least 90% identical in amino acid sequence to residues 1-479 of SEQ ID NO:2, wherein said sequence comprises a POZ domain corresponding to amino acid residues 61-178 of SEQ ID NO:2.
A isolated polynucleotide encoding a polypeptide comprising a sequence of amino acid residues that is at least 80% identical in amino acid sequence to residues 1-479 of SEQ ID NO:2, wherein said sequence comprises a POZ domain corresponding to amino acid residues 61-178 of SEQ ID NO:2.
An isolated polynucleotide comprising the sequence of nucleotide 1 to nucleotide 1437 of SEQ ID NO:4.
An oligonucleotide probe or primer comprising at least 14 contiguous nucleotides of a polynucleotide of SEQ ID NO:4 or a sequence complementary to SEQ ID NO:4.
An expression vector comprising the following operably linked elements:
- a transcription promoter;
- a DNA segment encoding a polypeptide comprising a sequence of amino acid residues that is at least 80% identical in amino acid sequence to residues 1-479 of SEQ ID NO:2, wherein said sequence comprises a POZ domain corresponding to amino acid residues 61-178 of SEQ ID NO:2;
- and
- a transcription terminator.
A cultured cell into which has been introduced an expression vector comprising the following operably linked elements:
- a transcription promoter;
- a DNA segment encoding a polypeptide comprising a sequence of amino acid residues that is at least 80% identical in amino acid sequence to residues 1-479 of SEQ ID NO:2, wherein said sequence comprises a POZ domain corresponding to amino acid residues 61-178 of SEQ ID NO:2;
- and
- a transcription terminator;
- wherein said cell expresses said polypeptide encoded by said DNA segment.
A method of producing a polypeptide comprising:
- culturing a cell into which has been introduced an expression vector comprising the following operably linked elements:
- a transcription promoter;
- a DNA segment encoding a polypeptide comprising a sequence of amino acid residues that is at least 80% identical in amino acid sequence to residues 1-479 of SEQ ID NO:2, wherein said sequence comprises a POZ domain corresponding to amino acid residues 61-178 of SEQ ID NO:2;
- and
- a transcription terminator;
- whereby said cell expresses said polypeptide encoded by said DNA segment;
- and
- recovering said expressed polypeptide.
A pharmaceutical composition comprising a polypeptide, said polypeptide comprising a sequence of amino acid residues that is at least 80% identical in amino acid sequence to residues 1-479 of SEQ ID NO:2, wherein said sequence comprises a POZ domain corresponding to amino acid residues 61-178 of SEQ ID NO:2;
- in combination with a pharmaceutically acceptable vehicle.
An antibody that specifically binds to an epitope of a polypeptide comprising a sequence of amino acid residues that is at least 80% identical in amino acid sequence to residues 1-479 of SEQ ID NO:2, wherein said sequence comprises a POZ domain corresponding to amino acid residues 61-178 of SEQ ID NO:2.
A binding protein that specifically binds to an epitope of a polypeptide comprising a sequence of amino acid residues that is at least 80% identical in amino acid sequence to residues 1-479 of SEQ ID NO:2, wherein said sequence comprises a POZ domain corresponding to amino acid residues 61-178 of SEQ ID NO:2.
A method for detecting a genetic abnormality in a patient, comprising:
- obtaining a genetic sample from a patient;
- incubating the genetic sample with a polynucleotide comprising at least 14 contiguous nucleotides of SEQ ID NO:1 or the complement of SEQ ID NO:1, under conditions wherein said polynucleotide will hybridize to complementary polynucleotide sequence, to produce a first reaction product;
- comparing said first reaction product to a control reaction product, wherein a difference between said first reaction product and said control reaction product is indicative of a genetic abnormality in the patient.
Dependencies are inferred from the claim text.